The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Full Access

The effects of clozapine on cognitive functioning in treatment- resistant schizophrenic patients

Published Online:https://doi.org/10.1176/jnp.9.2.240

This study examined the cognitive functioning of 10 treatment-resistant schizophrenic patients after a minimum of a 1-year trial on clozapine. Results indicated significant improvements on prorated Wechsler Adult Intelligence Scale-Revised (WAIS-R) Full Scale, Verbal, and Performance IQs and on the WAIS-R Similarities and Digit Symbol subtests. A trend was also found for improvement on the Wisconsin Card Sorting Test. It was concluded that clozapine treatment is associated with global cognitive improvements in patients with treatment-resistant schizophrenia. Clozapine treatment may also improve performance on the Wisconsin Card Sorting Test in a subset of patients. Improvement did not appear to be related to the reduction of any cognitive effects of the typical neuroleptics upon their discontinuation.